June Raine, MHRA chief executive (AP Photo/Frank Augstein, Pool)
February 16, 2023 03:21 PM ESTUpdated 04:01 PM
Pharma
FDA+

UK could al­low rec­i­p­ro­cal drug ap­provals with US FDA as soon as 2024

Paul Schloesser

Associate Editor

An in­tel­lec­tu­al prop­er­ty law firm says that re­cent guid­ance from the UK’s Med­i­cines and Health­care prod­ucts Reg­u­la­to­ry Agency hints at the pos­si­bil­i­ty of the agency …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times